|
| Status |
Public on Mar 14, 2022 |
| Title |
S_100437 |
| Sample type |
RNA |
| |
|
| Source name |
FFPE bladder cancer
|
| Organism |
Homo sapiens |
| Characteristics |
treatment: LY3009806 + Docetaxel
primary site: Non-Bladder
|
| Treatment protocol |
Not Applicable
|
| Growth protocol |
Not Applicable
|
| Extracted molecule |
total RNA |
| Extraction protocol |
NOT PROVIDED
|
| Label |
biotin
|
| Label protocol |
RNA was amplified, fragmented and biotinylated using the WT-Ovation FFPE system (NuGen, San Carlos, CA) according to the manufacturer’s recommendations with minor modifications.
|
| |
|
| Hybridization protocol |
Samples were hybridized using Affymetrix hybridization kit materials and protocols.
|
| Scan protocol |
Affymetrix GeneChip Scanner 3000 7G.
|
| Data processing |
Data was normalized using SCAN (SCAN.UPC package from Bioconductor).
Probe group file: Decipher-v1.r1.pgf
Meta-probeset file: Decipher-v1.r1.mps
Background probe file: Decipher-v1.r1.antigenomic.bgp
CEL layout file: Decipher-v1.r1.clf
Quality Control Content file: Decipher-v1.r1.qcc
|
| |
|
| Submission date |
Mar 09, 2022 |
| Last update date |
Mar 14, 2022 |
| Contact name |
Erik Roy Rasmussen |
| E-mail(s) |
[email protected]
|
| Phone |
6315251757
|
| Organization name |
Eli Lilly
|
| Street address |
430 East 29th Street
|
| City |
New York |
| State/province |
NY |
| ZIP/Postal code |
10016 |
| Country |
USA |
| |
|
| Platform ID |
GPL22995 |
| Series (1) |
| GSE198269 |
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial |
|
